Immunological effects of supervised exercise in long COVID in adults: A secondary analysis of a randomized crossover trial.

Physiol RepSep 1, 2026
Clinical ResearchInfectious DiseasesPhysical Medicine & RehabilitationOpen access

Nora García-Alonso, Mikel Izquierdo, Hugo Arasanz et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of a randomized crossover trial evaluated the immunological effects of a 6-week supervised exercise program in adults with long COVID. The study found that while five immune variables showed nominal significance, none remained significant after correction for multiple comparisons, indicating no substantial immunological changes associated with exercise.

Key findings

  • Five immune variables showed nominal significance, including IL-1β and IL-10.
  • No significant changes were observed in innate immune populations.
  • Supervised exercise demonstrated short-term immunological safety in adults with long COVID.

Why it matters

Understanding the immunological effects of exercise in long COVID patients is crucial for developing safe rehabilitation strategies. This study suggests that moderate-intensity exercise does not adversely affect immune function in this population.

Source

PubMed · PMID 42665974Free full text on PubMed Central

Published in Physiol Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.